Peroxisome Dysfunction Validation in PD
Experiment Overview
flowchart TD
experiments_peroxisome_dysfunc["Peroxisome Dysfunction Validation in Parkinsons "]
experiments_peroxisome_dysfunc["Validation"]
experiments_peroxisome_dysfunc -->|"related to"| experiments_peroxisome_dysfunc
style experiments_peroxisome_dysfunc fill:#81c784,stroke:#333,color:#000
experiments_peroxisome_dysfunc["Experiment"]
experiments_peroxisome_dysfunc -->|"related to"| experiments_peroxisome_dysfunc
style experiments_peroxisome_dysfunc fill:#81c784,stroke:#333,color:#000
experiments_peroxisome_dysfunc["Hypothesis"]
experiments_peroxisome_dysfunc -->|"related to"| experiments_peroxisome_dysfunc
style experiments_peroxisome_dysfunc fill:#81c784,stroke:#333,color:#000
experiments_peroxisome_dysfunc["represents"]
experiments_peroxisome_dysfunc -->|"related to"| experiments_peroxisome_dysfunc
style experiments_peroxisome_dysfunc fill:#81c784,stroke:#333,color:#000
style experiments_peroxisome_dysfunc fill:#4fc3f7,stroke:#333,color:#000
Hypothesis: Peroxisome dysfunction represents an upstream driver in PD pathogenesis, connecting lipid dysregulation, mitochondrial impairment, and alpha-synuclein aggregation.
Primary Objective: Validate peroxisome dysfunction in PD patient samples and test therapeutic interventions targeting peroxisome restoration.
Study Design: Multi-phase (preclinical + clinical)
Phase 1: Biomarker Discovery (Preclinical)
Specific Aims
...Peroxisome Dysfunction Validation in PD
Experiment Overview
Mermaid diagram (expand to render)
Hypothesis: Peroxisome dysfunction represents an upstream driver in PD pathogenesis, connecting lipid dysregulation, mitochondrial impairment, and alpha-synuclein aggregation.
Primary Objective: Validate peroxisome dysfunction in PD patient samples and test therapeutic interventions targeting peroxisome restoration.
Study Design: Multi-phase (preclinical + clinical)
Phase 1: Biomarker Discovery (Preclinical)
Specific Aims
Aim 1: Characterize peroxisome parameters in iPSC-derived dopaminergic neurons from PD patients vs. healthy controls
Aim 2: Test whether peroxisome dysfunction promotes alpha-synuclein aggregation in neurons
Aim 3: Evaluate therapeutic interventions (PPAR agonists, plasmalogen supplementation)Methods
| Parameter | Method | Samples |
|-----------|--------|---------|
| Peroxisome count | TOM20/PEX14 immunostaining | iPSC neurons |
| VLCFA levels | LC-MS/MS | Cell lysates, media |
| Plasmalogen levels | LC-MS/MS | Cell membranes |
| Catalase activity | Colorimetric assay | Cell lysates |
| Alpha-synuclein aggregation | pSer129 IF, ThT fluorescence | Neurons |
| Mitochondrial function | Seahorse XF | Neurons |
Interventions to Test
PPAR agonists (fenofibrate, rosiglitazone)
Plasmalogen supplementation (1-O-hexadecyl-sn-glycerol)
Catalase overexpression (AAV vector)Phase 2: Clinical Biomarker Study
Study Design
- Type: Case-control biomarker study
- Cohort: 150 PD patients, 150 age-matched controls
- Primary Endpoints: VLCFA ratios, plasmalogen levels in plasma/CSF
Inclusion Criteria
- PD diagnosed by UK Brain Bank criteria
- Age 40-80 years
- Disease duration 1-10 years
- H&Y stage 1-3
Biomarker Measurements
| Biomarker | Method | Sample | Rationale |
|-----------|--------|--------|-----------|
| C26:0/C22:0 ratio | LC-MS/MS | Plasma, CSF | VLCFA accumulation |
| Plasmalogens (PC, PE) | LC-MS/MS | Plasma, CSF | Plasmalogen deficiency |
| Catalase activity | Colorimetric | Plasma | Antioxidant capacity |
| PEX gene expression | qPCR | PBMCs | Peroxisome biogenesis |
Phase 3: Therapeutic Trial
Trial Design
- Type: Randomized, double-blind, placebo-controlled
- Intervention: PPAR agonist (fenofibrate) 160mg daily
- Duration: 12 months
- Primary Endpoint: Change in MDS-UPDRS motor score
Rationale for Fenofibrate
- FDA-approved for dyslipidemia (safety established)
- Demonstrated peroxisome proliferation in preclinical models
- Blood-brain barrier penetration demonstrated
- Existing safety data in elderly patients
Sample Size Calculation
- Power: 80%
- Alpha: 0.05
- Expected effect: 4-point MDS-UPDRS improvement
- Dropout: 15%
- N: 120 per arm (240 total)
Study Timeline
| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | 6 months | iPSC characterization complete |
| Phase 2 | 12 months | Biomarker study complete |
| Phase 3 | 24 months | Clinical trial complete |
Success Criteria
Significant peroxisome abnormalities in PD neurons (p<0.01)
Therapeutic intervention reduces alpha-synuclein aggregation by >30%
Biomarkers distinguish PD patients from controls (AUC >0.80)
Fenofibrate shows preliminary efficacy signal in Phase 3Risks and Mitigations
| Risk | Mitigation |
|------|-------------|
| iPSC differentiation failure | Use established protocols, quality controls |
| Biomarker variability | Standardize sample collection, use internal standards |
| Insufficient drug penetration | Use fenofibrate, ensure BBB penetration data |
| Insufficient sample size | Power calculations, multicenter recruitment |
Budget Estimate
- Phase 1: $150,000
- Phase 2: $300,000
- Phase 3: $1,500,000
- Total: $1,950,000
References
[Stehfest et al., Redox Biol (2022)](https://pubmed.ncbi.nlm.nih.gov/35066423/)
[Joers et al., Front Cell Neurosci (2020)](https://pubmed.ncbi.nlm.nih.gov/32765238/)